CN116802738A - 为个体化癌症疫苗选择新抗原 - Google Patents

为个体化癌症疫苗选择新抗原 Download PDF

Info

Publication number
CN116802738A
CN116802738A CN202180086487.8A CN202180086487A CN116802738A CN 116802738 A CN116802738 A CN 116802738A CN 202180086487 A CN202180086487 A CN 202180086487A CN 116802738 A CN116802738 A CN 116802738A
Authority
CN
China
Prior art keywords
tumor
leu
ser
ala
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180086487.8A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·赫克曼
弗兰克·威廉·史密茨
迈克尔·沃格松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazon Technologies Inc
Original Assignee
Amazon Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazon Technologies Inc filed Critical Amazon Technologies Inc
Publication of CN116802738A publication Critical patent/CN116802738A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202180086487.8A 2020-11-06 2021-11-05 为个体化癌症疫苗选择新抗原 Pending CN116802738A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110711P 2020-11-06 2020-11-06
US63/110,711 2020-11-06
PCT/US2021/058162 WO2022098936A1 (en) 2020-11-06 2021-11-05 Selecting neoantigens for personalized cancer vaccine

Publications (1)

Publication Number Publication Date
CN116802738A true CN116802738A (zh) 2023-09-22

Family

ID=78695860

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180086487.8A Pending CN116802738A (zh) 2020-11-06 2021-11-05 为个体化癌症疫苗选择新抗原

Country Status (5)

Country Link
US (1) US20230197192A1 (https=)
EP (1) EP4241274A1 (https=)
JP (1) JP2023549342A (https=)
CN (1) CN116802738A (https=)
WO (1) WO2022098936A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
WO2025128926A1 (en) 2023-12-13 2025-06-19 Amazon Technologies, Inc. Methods of identifying and treating individuals with elevated cancer risk
US20250197924A1 (en) 2023-12-15 2025-06-19 Amazon Technologies, Inc. Methods for selection and combination of sequencing results from biological samples for neoantigen scoring
WO2026073127A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Dual assay to boost accuracy of detected actionable variants in liquid biopsy
WO2026072916A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Structural variant detection in circulating tumor dna

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106638A1 (en) * 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US20170198351A1 (en) * 2016-01-13 2017-07-13 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor dna
US20190017050A1 (en) * 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2019050994A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
WO2020065023A1 (en) * 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
KR20150093658A (ko) * 2012-10-09 2015-08-18 파이브3 제노믹스, 엘엘씨 종양 클론형성능 분석을 위한 시스템 및 방법
AU2019404547B2 (en) * 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106638A1 (en) * 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
JP2019501967A (ja) * 2015-12-16 2019-01-24 グリットストーン オンコロジー インコーポレイテッド 新生抗原の特定、製造、および使用
US20170198351A1 (en) * 2016-01-13 2017-07-13 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor dna
US20190017050A1 (en) * 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2019050994A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
US20200363414A1 (en) * 2017-09-05 2020-11-19 Gritstone Oncology, Inc. Neoantigen Identification for T-Cell Therapy
WO2020065023A1 (en) * 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes

Also Published As

Publication number Publication date
US20230197192A1 (en) 2023-06-22
JP2023549342A (ja) 2023-11-24
EP4241274A1 (en) 2023-09-13
WO2022098936A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
JP7712970B2 (ja) ホットスポットを利用した新生抗原の特定
JP7651623B2 (ja) 新生抗原の特定、製造、及び使用
CN111868080B (zh) 利用泛等位基因模型进行的新抗原鉴别
JP7763588B2 (ja) Ｔ細胞療法用の新生抗原の特定法
CN116802738A (zh) 为个体化癌症疫苗选择新抗原
CN112534045A (zh) 获得肿瘤特异性t细胞受体的方法
US20230173045A1 (en) Ranking neoantigens for personalized cancer vaccine
JP2021503897A (ja) 新生抗原のためのジャンクションエピトープ提示の低減
MX2015000483A (es) Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
RS62390B1 (sr) Izbor neoepitopa kao ciljeva specifičnih za bolest za terapiju sa povećanom efikasnošću
US20220241331A1 (en) Identification of recurrent mutated neopeptides
KR20220108045A (ko) 공유 후보 항원 및 공유 항원-특이적 t 림프구 쌍을 확인 및 검증하기 위한 방법 및 시스템
CN117321690A (zh) 用于优化肿瘤疫苗抗原对异质性恶性肿瘤的覆盖的方法
US20240024439A1 (en) Administration of anti-tumor vaccines
CN112533630A (zh) 用于癌症的个体化疫苗
US20250003004A1 (en) Personalized Longitudinal Analysis of Circulating Material to Monitor and Adapt Neoantigen Cancer Vaccines
JP7851893B2 (ja) Ｔ細胞療法用の新生抗原の特定法
HK40020601A (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination